Matthew Lee

Matthew Lee

Auto-generated profile, based on publicly available information

Matthew Lee

Institute for Immunology & Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Ahmad OzairAhmad Ozair
Ahmad Ozair
JDJan Drappatz
Jan Drappatz
XYXiaobu Ye
Xiaobu Ye
SPSen Peng
Sen Peng
LRLisa R. Rogers
Lisa R. Rogers
Purpose: Patients with glioblastoma (GBM) have a dismal prognosis. Although the DNA alkylating agent temozolomide (TMZ) is the mainstay of chemotherapy, therapeutic resistance rapidly develops in patients. Base excision repair inhibitor TRC102 (methoxyamine) reverses TMZ resistance in preclinical glioma models. We aimed to investigate the efficacy and safety of oral TRC102+TMZ in recurrent GBM (rGBM). Patients and Methods: A preregistered (NCT02395692), nonrandomized, multicenter, phase 2 clinical trial (BERT) was planned and conducted through the Adult Brain Tumor Consortium (ABTC-1402). Arm 1 included patients with bevacizumab-naïve GBM at the first recurrence, with the primary endpoint of response rates. If sufficient activity was identified, a second arm was planned for the bevacizumab-refractory patients. The secondary endpoints were overall survival (OS), progression-free survival (PFS), PFS at 6 months (PFS6), and toxicity. Results: Arm 1 enrolled 19 patients with a median of two treatment cycles. Objective responses were not observed; hence, arm 2 did not open. The median OS was 11.1 months [95% confidence interval (CI), 8.2–17.9]. The median PFS was 1.9 months (95% CI, 1.8–3.7). The PFS6 was 10.5% (95% CI, 1.3%–33.1%). Most toxicities were grades 1 and 2, with two grade 3 lymphopenias and one grade 4 thrombocytopenia. Two patients with PFS ≥ 17 months and OS > 32 months were deemed “extended survivors.” RNA sequencing of tumor tissue, obtained at diagnosis, demonstrated significantly enriched signatures of DNA damage response (DDR), chromosomal instability (CIN70, CIN25), and cellular proliferation (PCNA25) in “extended survivors.” Conclusions: These findings confirm the safety and feasibility of TRC102+TMZ in patients with rGBM. They also warrant further evaluation of combination therapy in biomarker-enriched trials enrolling GBM patients with baseline hyperactivated DDR pathways.

20 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MLMatthew E. Lee
Matthew E. Lee
JKJaesik Kim
Jaesik Kim
MIMatei Ionita
Matei Ionita
MMMichelle L. McKeague
Michelle L. McKeague
JLJonghyun Lee
Jonghyun Lee
EWE. John Wherry
E. John Wherry
The human immune system is composed of ∼30-50 distinct cell types, each of which can exist in different states of activation or differentiation. Indeed, the mammalian immune system has evolved to sense and respond to infections, cancers, injuries, and changes in tissue or host homeostasis (1). Moreover, an increasingly large fraction of approved drugs target the immune system directly, and/or cause immune changes (2–4). A key feature of the immune system is to store some of this information, for example as innate or adaptive immune memory (5). In addition, rewiring of immune network architecture induced by disease, environmental exposures, drug treatments, and/or chronological age allows the immune system to store information in the pattern of connections and activity across populations of immune cells. This ensemble information storage, in addition to changes to individual cells, functions as a major way the immune system encodes aspects of immune history and future potential. Genetic information can identify inherited risk alleles, but cannot capture the continual remodeling of the immune system shaped by exposures, infection, inflammation, therapy, and aging (6, 7). To define and use such ensemble immunotypes, we developed a self-supervised deep learning framework that transforms high-dimensional immune profiles into representations of immune health. MAESTRO (MAsked Encoding Set TRansformer with self-distillatiOn) encodes a set of cells from an individual into an embedding that captures immune cell population-level organization. Pretrained on 1,792 peripheral blood samples comprising over 418 million immune cells across 13 clinical diagnoses, MAESTRO learns immune fingerprints that are stable within individuals yet diverse across populations, states of health, disease, and treatment, providing a quantitative basis for comparing immune states across individuals and over time. These fingerprints capture immune architecture beyond coarse cell type proportions, enabling patient-efficient clinical prediction using simple task specific models. MAESTRO model embeddings retain a temporal dimension of immune history and potential, reflecting signatures of past exposures and baseline features that predict future immune responses. Finally, we demonstrate a translational precision immunotherapy application by testing this approach in metastatic Pancreatic Ductal Adenocarcinoma (PDAC), where pretreatment immune landscape circuitry maps enable patient stratification and therapeutic response prediction. Overall, we developed a large, attention-based model that captures deep network architecture of immune states through self- supervised representations of immune cytometry data as a reusable foundation for precision immunology, converting immune complexity into clinically actionable embeddings for diagnosis, monitoring, and therapy selection.

6 August 2024
Verified
Other
Open access
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Ahmad OzairAhmad Ozair
Ahmad Ozair
JDJan Drappatz
Jan Drappatz
XYXiaobu Ye
Xiaobu Ye
SPSen Peng
Sen Peng
LRLisa R. Rogers
Lisa R. Rogers
Correlation between MGMT mRNA and MGTM protein abundance values in glioblastoma from the CPTAC database.

6 August 2024
Verified
Other
Open access
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Ahmad OzairAhmad Ozair
Ahmad Ozair
JDJan Drappatz
Jan Drappatz
XYXiaobu Ye
Xiaobu Ye
SPSen Peng
Sen Peng
LRLisa R. Rogers
Lisa R. Rogers
Purpose:Patients with glioblastoma (GBM) have a dismal prognosis. Although the DNA alkylating agent temozolomide (TMZ) is the mainstay of chemotherapy, therapeutic resistance rapidly develops in patients. Base excision repair inhibitor TRC102 (methoxyamine) reverses TMZ resistance in preclinical glioma models. We aimed to investigate the efficacy and safety of oral TRC102+TMZ in recurrent GBM (rGBM).Patients and Methods:A preregistered (NCT02395692), nonrandomized, multicenter, phase 2 clinical trial (BERT) was planned and conducted through the Adult Brain Tumor Consortium (ABTC-1402). Arm 1 included patients with bevacizumab-naïve GBM at the first recurrence, with the primary endpoint of response rates. If sufficient activity was identified, a second arm was planned for the bevacizumab-refractory patients. The secondary endpoints were overall survival (OS), progression-free survival (PFS), PFS at 6 months (PFS6), and toxicity.Results:Arm 1 enrolled 19 patients with a median of two treatment cycles. Objective responses were not observed; hence, arm 2 did not open. The median OS was 11.1 months [95% confidence interval (CI), 8.2–17.9]. The median PFS was 1.9 months (95% CI, 1.8–3.7). The PFS6 was 10.5% (95% CI, 1.3%–33.1%). Most toxicities were grades 1 and 2, with two grade 3 lymphopenias and one grade 4 thrombocytopenia. Two patients with PFS ≥ 17 months and OS > 32 months were deemed “extended survivors.” RNA sequencing of tumor tissue, obtained at diagnosis, demonstrated significantly enriched signatures of DNA damage response (DDR), chromosomal instability (CIN70, CIN25), and cellular proliferation (PCNA25) in “extended survivors.”Conclusions:These findings confirm the safety and feasibility of TRC102+TMZ in patients with rGBM. They also warrant further evaluation of combination therapy in biomarker-enriched trials enrolling GBM patients with baseline hyperactivated DDR pathways.


6 August 2024
Verified
Other
Open access
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Ahmad OzairAhmad Ozair
Ahmad Ozair
JDJan Drappatz
Jan Drappatz
XYXiaobu Ye
Xiaobu Ye
SPSen Peng
Sen Peng
LRLisa R. Rogers
Lisa R. Rogers
Correlation between MGMT and MPG protein levels in glioblastoma from the CPTAC database.